User:MaryGaulke/sandbox/Intarcia mockup marked up

Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. The company engages in research and development for the prevention and treatment of chronic disorders and infectious diseases, including diabetes, obesity and HIV. Its Medici product, which has not yet been approved by the FDA, is a matchstick-sized device that is inserted under the skin and delivers medicine over the course of six or 12 months, with the intention of improving dosage consistency and patient compliance.

History
It Intarcia was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.

In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively. By 2012, Kurt Graves had replaced Karling Leung as President and CEO. Kurt Graves has been with Intarcia since joined the company in August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012. Intarcia acquired biotechnology company Phoundry Pharmaceuticals, based in Research Triangle Park, North Carolina, in 2015.

Research and development
In May 2016, the company announced that it had completed Phase 3 clinical trials for its GLP-1 product. , Intarcia is engaged in development of claims the product, referred to as ITCA 650, is a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, t T he therapeutic consists of exenatide delivered via its Medici Drug Delivery System, "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides". The Medici system is a drug pump the approximate size of a matchstick that is injected underneath the patient's skin. Because the product would only require replacement every six or 12 months, it would be intended to improve patient compliance in addition to dosage consistency.

In November 2017, the FDA rejected the product for approval, citing manufacturing issues. In December 2018, the company said it was intending to re-submit its application with the FDA.

, the company is developing an HIV prevention and treatment product that would also use the Medici delivery technology, with investment from the Bill & Melinda Gates Foundation.

Investors
In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. Other Investors investors include Greenspring Associates, Alta Partners and Granite Venture Partners.

In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors. In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650. In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch. In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.

In December 2016, Intarcia received a $140M investment from the Bill & Melinda Gates Foundation to support development of HIV treatment and prevention technology. The company raised another $200M in September 2017.